New cardiovascular and pulmonary therapeutic strategies based on the angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis

International Journal of Hypertension

Volumn 2012, Issue , 2012, Pages

  Ferreira, Anderson J ^a   Murça, Tatiane M ^a   Fraga Silva, Rodrigo A ^a   Castro, Carlos Henrique ^b   Raizada, Mohan K ^c   Santos, Robson A S ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ALDOSTERONE ANTAGONIST; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; ANGIOTENSIN[1-9]; BLEOMYCIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; G PROTEIN COUPLED RECEPTOR; ISOPRENALINE; MONOCROTALINE; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG STABILITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; LUNG CANCER; LUNG DISEASE; LUNG FIBROSIS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN HYDROLYSIS; PULMONARY HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SUPRAVENTRICULAR TACHYCARDIA;

EID: 84861511222     PISSN: 20900384     EISSN: 20900392     Source Type: Journal    
DOI: 10.1155/2012/147825     Document Type: Review

References (145)

1. Hall J. E., Guyton A. C., Mizelle H. L., Role of the renin-angiotensin system in control of sodium excretion and arterial pressure. Acta Physiologica Scandinavica, Supplement 1990 139 591 48 62 (Pubitemid 20232632)
2. Guyton A. C., Kidneys and fluids in pressure regulation: small volume but large pressure changes. Hypertension 1992 19 1 I2 I8 2-s2.0-0026592420
3. Santos R. A. S., Campagnole-Santos M. J., Andrade S. P., Angiotensin-(17): an update. Regulatory Peptides 2000 91 13 45 62 2-s2.0-0034725602 10.1016/S0167-0115(00)00138-5
4. Marshall R. P., The pulmonary renin-angiotensin system. Current Pharmaceutical Design 2003 9 9 715 722 2-s2.0-0037240665 10.2174/ 1381612033455431 (Pubitemid 36367593)
5. Ferrario C. M., Strawn W. B., Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. The American Journal of Cardiology 2006 98 1 121 128 2-s2.0-33745162185 10.1016/j.amjcard. 2006.01.059 (Pubitemid 43902687)
6. Kokubu T., Ueda E., Joh T., Nishimura K., Purification and properties of angiotensin I-converting enzyme in human lung and its role on the metabolism of vasoactive peptides in pulmonary circulation. Advances in Experimental Medicine and Biology B 1979 120 467 475 2-s2.0-0018556554
7. Inagami T., A memorial to Robert Tiegerstedt: the centennial of renin discovery. Hypertension 1998 32 6 953 957 2-s2.0-0032247579
8. Touyz R. M., Berry C., Recent advances in angiotensin II signaling. Brazilian Journal of Medical and Biological Research 2002 35 9 1001 1015 2-s2.0-0036762815 (Pubitemid 35452880)
9. Matsusaka T., Ichikawa I., Biological functions of angiotensin and its receptors. Annual Review of Physiology 1997 59 395 412 2-s2.0-0030948534 10.1146/annurev.physiol.59.1.395 (Pubitemid 27142448)
10. Allen A. M., Zhuo J., Mendelsohn F. A. O., Localization and function of angiotensin AT1 receptors. American Journal of Hypertension 2000 13 1 31S 38S 2-s2.0-0033960508 (Pubitemid 30103853)
11. Kim S., Iwao H., Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacological Reviews 2000 52 1 11 34 2-s2.0-0034100147 (Pubitemid 30127593)
12. Mehta P. K., Griendling K. K., Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. American Journal of PhysiologyCell Physiology 2007 292 1 C82 C97 2-s2.0-33846362954 10.1152/ajpcell.00287.2006 (Pubitemid 46127306)
13. Horiuchi M., Hayashida W., Kambe T., Yamada T., Dzau V. J., Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activated protein kinase phosphatase-1 and induces apoptosis. Journal of Biological Chemistry 1997 272 30 19022 19026 2-s2.0-0030789196 10.1074/jbc.272.30.19022 (Pubitemid 27318258)
14. Touyz R. M., Endemann D., He G., Li J. S., Schiffrin E. L., Role of AT2 receptors in angiotensin II-stimulated contraction of small mesenteric arteries in young SHR. Hypertension 1999 33 1 366 372 2-s2.0-0032608801 (Pubitemid 29065686)
15. le Tran Y., Forster C., Angiotensin-(17) and the rat aorta: modulation by the endothelium. Journal of Cardiovascular Pharmacology 1997 30 5 676 682 2-s2.0-0030844113 10.1097/00005344-199711000-00019 (Pubitemid 27524509)
16. Santos R. A. S., Simoes e Silva A. C., Maric C., Silva D. M. R., Machado R. P., De Buhr I., Heringer-Walther S., Pinheiro S. V. B., Lopes M. T., Bader M., Mendes E. P., Lemos V. S., Campagnole-Santos M. J., Schultheiss H. P., Speth R., Walther T., Angiotensin-(17) is an endogenous ligand for the G protein-coupled receptor Mas. Proceedings of the National Academy of Sciences of the United States of America 2003 100 14 8258 8263 2-s2.0-0037478671 10.1073/pnas.1432869100 (Pubitemid 36842532)
17. Santos R. A. S., Ferreira A. J., Nadu A. P., Braga A. N. G., De Almeida A. P., Campagnole-Santos M. J., Baltatu O., Iliescu R., Reudelhuber T. L., Bader M., Expression of an angiotensin-(17)-producing fusion protein produces cardioprotective effects in rats. Physiological Genomics 2004 17 292 299 2-s2.0-3042723695 10.1152/physiolgenomics.00227.2003 (Pubitemid 38924174)
18. Grobe J. L., Mecca A. P., Lingis M., Shenoy V., Bolton T. A., Machado J. M., Speth R. C., Raizada M. K., Katovich M. J., Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(17). American Journal of PhysiologyHeart and Circulatory Physiology 2007 292 2 H736 H742 2-s2.0-33846987938 10.1152/ajpheart.00937.2006
19. Mercure C., Yogi A., Callera G. E., Aranha A. B., Bader M., Ferreira A. J., Santos R. A. S., Walther T., Touyz R. M., Reudelhuber T. L., Angiotensin(17) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circulation Research 2008 103 11 1319 1326 2-s2.0-58149352445 10.1161/CIRCRESAHA.108.184911
20. Nadu A. P., Ferreira A. J., Reudelhuber T. L., Bader M., Santos R. A. S., Reduced isoproterenol-induced renin-angiotensin changes and extracellular matrix deposition in hearts of TGR(A17)3292 rats. Journal of the American Society of Hypertension 2008 2 5 341 348 2-s2.0-51449095346 10.1016/j.jash.2008. 04.012
21. Ferreira A. J., Castro C. H., Guatimosim S., Almeida P. W. M., Gomes E. R. M., Dias-Peixoto M. F., Alves M. N. M., Fagundes-Moura C. R., Rentzsch B., Gava E., Almeida A. P., Guimarées A. M., Kitten G. T., Reudelhuber T., Bader M., Santos R. A. S., Attenuation of isoproterenol-induced cardiac fibrosis in transgenic rats harboring an angiotensin-(17)-producing fusion protein in the heart. Therapeutic Advances in Cardiovascular Disease 2010 4 2 83 96 2-s2.0-77950497363 10.1177/1753944709353426
22. Santiago N. M., Guimarães P. S., Sirvente R. A., Oliveira L. A. M., Irigoyen M. C., Santos R. A. S., Campagnole-Santos M. J., Lifetime overproduction of circulating angiotensin-(17) attenuates deoxycorticosterone acetate-salt hypertension-induced cardiac dysfunction and remodeling. Hypertension 2010 55 4 889 896 2-s2.0-77950505611 10.1161/HYPERTENSIONAHA.110. 149815
23. Savergnini S. Q., Beiman M., Lautner R. Q., De Paula-Carvalho V., Allahdadi K., Pessoa D. C., Costa-Fraga F. P., Fraga-Silva R. A., Cojocaru G., Cohen Y., Bader M., De Almeida A. P., Rotman G., Santos R. A. S., Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the Mas receptor. Hypertension 2010 56 1 112 120 2-s2.0-77953811506 10.1161/HYPERTENSIONAHA.110.152942
24. Vickers C., Hales P., Kaushik V., Dick L., Gavin J., Tang J., Godbout K., Parsons T., Baronas E., Hsieh F., Acton S., Patane M., Nichols A., Tummino P., Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. Journal of Biological Chemistry 2002 277 17 14838 14843 2-s2.0-18544378161 10.1074/jbc.M200581200 (Pubitemid 34952556)
25. Tipnis S. R., Hooper N. M., Hyde R., Karran E., Christie G., Turner A. J., A human homolog of angiotensin-converting enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase. Journal of Biological Chemistry 2000 275 43 33238 33243 2-s2.0-0034721906 10.1074/jbc.M002615200
26. Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M., Stagliano N., Donovan M., Woolf B., Robison K., Jeyaseelan R., Breitbart R. E., Acton S., A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 19. Circulation Research 2000 87 5 E1 E9 2-s2.0-0038053724
27. Ferrario C. M., The renin-angiotensin system: importance in physiology and pathology. Journal of Cardiovascular Pharmacology 1990 15, supplement 3 S1 S5 (Pubitemid 20115350)
28. Cargill R. I., Lipworth B. J., Lisinopril attenuates acute hypoxic pulmonary vasoconstriction in humans. Chest 1996 109 2 424 429 2-s2.0-0030026080 (Pubitemid 26058600)
29. Nicholls M. G., Richards A. M., Agarwal M., The importance of the renin-angiotensin system in cardiovascular disease. Journal of Human Hypertension 1998 12 5 295 299 2-s2.0-0031777979 (Pubitemid 28274359)
30. Marshall R. P., McAnulty R. J., Laurent G. J., Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor. American Journal of Respiratory and Critical Care Medicine 2000 161 6 1999 2004 2-s2.0-0034047028 (Pubitemid 30418143)
31. Orfanos S. E., Armaganidis A., Glynos C., Psevdi E., Kaltsas P., Sarafidou P., Catravas J. D., Dafni U. G., Langleben D., Roussos C., Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in acute lung injury. Circulation 2000 102 16 2011 2018 2-s2.0-0034680306
32. Fleming I., Kohlstedt K., Busse R., The tissue renin-angiotensin system and intracellular signalling. Current Opinion in Nephrology and Hypertension 2006 15 1 8 13 2-s2.0-33645736137
33. Schiffrin E. L., Vascular and cardiac benefits of angiotensin receptor blockers. The American Journal of Medicine 2002 113 5 409 418 2-s2.0-0036773028 10.1016/S0002-9343(02)01241-X (Pubitemid 35230007)
34. Ma T. K. W., Kam K. K. H., Yan B. P., Lam Y. Y., Renin-angiotensin- aldosterone system blockade for cardiovascular diseases: current status. British Journal of Pharmacology 2010 160 6 1273 1292 2-s2.0-77954056940 10.1111/j.1476-5381.2010.00750.x
35. Vijayaraghavan K., kvijaymd@gmail.com Deedwania P., Renin-angiotensin- aldosterone blockade for cardiovascular disease prevention. Cardiology Clinics 2011 29 1 137 156 10.1016/j.ccl.2010.11.003
36. Fourrier F., Chopin C., Wallaert B., Compared evolution of plasma fibronectin and angiotensin-converting enzyme levels in septic ARDS. Chest 1985 87 2 191 195 2-s2.0-0021931471 (Pubitemid 15174050)
37. Imai Y., Kuba K., Rao S., Huan Y., Guo F., Guan B., Yang P., Sarao R., Wada T., Leong-Poi H., Crackower M. A., Fukamizu A., Hui C. C., Hein L., Uhlig S., Slutsky A. S., Jiang C., Penninger J. M., Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005 436 7047 112 116 2-s2.0-21844460785 10.1038/nature03712 (Pubitemid 40966195)
38. Petty W. J., Miller A. A., McCoy T. P., Gallagher P. E., Tallant E. A., Torti F. M., Phase I and pharmacokinetic study of angiotensin-(17), an endogenous antiangiogenic hormone. Clinical Cancer Research 2009 15 23 7398 7404 2-s2.0-73149102795 10.1158/1078-0432.CCR-09-1957
39. Shenoy V., Ferreira A. J., Fraga-Silva R. A., Qi Y., Díez-Freire C., Dooies A., Jun J. Y., Sriramula S., Mariappan N., Pourang D., Venugopal C. S., Francis J., Reudelhuber T., Santos R. A., Patel J. M., Raizada M. K., Katovich M. J., The angiotensin-converting enzyme 2/angiogenesis-(17)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine 2010 182 8 1065 1072 2-s2.0-78049352553 10.1164/rccm.200912-1840OC
40. Uhal B. D., uhal@msu.edu Li X., Xue A., Gao X., Abdul-Hafez A., Regulation of alveolar epithelial cell survival by the ACE-2/angiotensin 17/ Mas axis. American Journal of PhysiologyLung Cellular and Molecular Physiology 2011 301 3 L269 L274 10.1152/ajplung.00222.2010
41. Chappell M. C., Pirro N. T., Sykes A., Ferrario C. M., Metabolism of angiotensin-(17) by angiotensin-converting enzyme. Hypertension 1998 31 1 362 367 2-s2.0-0031600505
42. Iyer S. N., Ferrario C. M., Chappell M. C., Angiotensin-(17) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension 1998 31 1 356 361 2-s2.0-0031601350
43. Davie A. P., McMurray J. J. V., Effect of angiotensin-(17) and bradykinin in patients with heart failure treated with an ACE inhibitor. Hypertension 1999 34 3 457 460 2-s2.0-0032888404 (Pubitemid 29426763)
44. Britto R. R., Santos R. A. S., Fagundes-Moura C. R., Khosla M. C., Campagnole-Santos M. J., Role of angiotensin-(17) in the modulation of the baroreflex in renovascular hypertensive rats. Hypertension 1997 30 3 549 556 2-s2.0-0030824948 (Pubitemid 27444230)
45. Oudit G. Y., Crackower M. A., Backx P. H., Penninger J. M., The role of ACE2 in cardiovascular physiology. Trends in Cardiovascular Medicine 2003 13 3 93 101 2-s2.0-0037383515 10.1016/S1050-1738(02)00233-5 (Pubitemid 36411803)
46. Guy J. L., Lambert D. W., Turner A. J., Porter K. E., Functional angiotensin-converting enzyme 2 is expressed in human cardiac myofibroblasts. Experimental Physiology 2008 93 5 579 588 2-s2.0-42649139921 10.1113/expphysiol.2007.040139 (Pubitemid 351595051)
47. Gallagher P. E., Ferrario C. M., Tallant E. A., Regulation of ACE2 in cardiac myocytes and fibroblasts. American Journal of PhysiologyHeart and Circulatory Physiology 2008 295 6 H2373 H2379 2-s2.0-57349151583 10.1152/ajpheart.00426.2008
48. Ferreira A. J., Shenoy V., Qi Y., Fraga-Silva R. A., Santos R. A.S., Katovich M. J., Raizada M. K., mraizada@phys.med.ufl.edu Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Experimental Physiology 2011 96 3 287 294 10.1113/expphysiol.2010.055277
49. Ferrario C. M., Jessup J., Chappell M. C., Averill D. B., Brosnihan K. B., Tallant E. A., Diz D. I., Gallagher P. E., Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005 111 20 2605 2610 2-s2.0-19644384705 10.1161/CIRCULATIONAHA.104.510461 (Pubitemid 40740859)
50. Keidar S., Gamliel-Lazarovich A., Kaplan M., Pavlotzky E., Hamoud S., Hayek T., Karry R., Abassi Z., Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. Circulation Research 2005 97 9 946 953 2-s2.0-27644585370 10.1161/01.RES. 0000187500.24964.7A (Pubitemid 41552681)
51. Kaiqiang Ji, Minakawa M., Fukui K., Suzuki Y., Fukuda I., Olmesartan improves left ventricular function in pressure-overload hypertrophied rat heart by blocking angiotensin II receptor with synergic effects of upregulation of angiotensin converting enzyme 2. Therapeutic Advances in Cardiovascular Disease 2009 3 2 103 111 2-s2.0-66149130760 10.1177/1753944708098691
52. Crackower M. A., Sarao R., Oudit G. Y., Yagil C., Kozieradzki I., Scanga S. E., Oliveira-dos-Santos A. J., Da Costa J., Zhang L., Pei Y., Scholey J., Ferrarlo C. M., Manoukian A. S., Chappell M. C., Backx P. H., Yagil Y., Penninger J. M., Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002 417 6891 822 828 2-s2.0-0037142101 10.1038/nature00786 (Pubitemid 34670323)
53. Gurley S. B., Allred A., Le T. H., Griffiths R., Mao L., Philip N., Haystead T. A., Donoghue M., Breitbart R. E., Acton S. L., Rockman H. A., Coffman T. M., Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. Journal of Clinical Investigation 2006 116 8 2218 2225 2-s2.0-33746724157 10.1172/JCI16980 (Pubitemid 44162331)
54. Yamamoto K., Ohishi M., Katsuya T., Ito N., Ikushima M., Kaibe M., Tatara Y., Shiota A., Sugano S., Takeda S., Rakugi H., Ogihara T., Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 2006 47 4 718 726 2-s2.0-33645834948 10.1161/01.HYP.0000205833.89478.5b (Pubitemid 43740244)
55. Trask A. J., Averill D. B., Ganten D., Chappell M. C., Ferrario C. M., Primary role of angiotensin-converting enzyme-2 in cardiac production of angiotensin-(17) in transgenic Ren-2 hypertensive rats. American Journal of PhysiologyHeart and Circulatory Physiology 2007 292 6 H3019 H3024 2-s2.0-34447126601 10.1152/ajpheart.01198.2006 (Pubitemid 47084554)
56. Kassiri Z., Zhong J., Guo D., Basu R., Wang X., Liu P. P., Scholey J. W., Penninger J. M., Oudit G. Y., Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circulation: Heart Failure 2009 2 5 446 455 2-s2.0-70350457666 10.1161/CIRCHEARTFAILURE.108.840124
57. Zhong J., Guo D., Chen C. B., Wang W., Schuster M., Loibner H., Penninger J. M., Scholey J. W., Kassiri Z., Oudit G. Y., Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Hypertension 2011 57 314 322 2-s2.0-78650582456 10.1161/HYPERTENSIONAHA.110.164244
58. Trask A. J., Groban L., Westwood B. M., Varagic J., Ganten D., Gallagher P. E., Chappell M. C., Ferrario C. M., Inhibition of angiotensin-converting enzyme 2 exacerbates cardiac hypertrophy and fibrosis in ren-2 hypertensive rats. American Journal of Hypertension 2010 23 6 687 693 2-s2.0-77952511816 10.1038/ajh.2010.51
59. Huentelman M. J., Grobe J. L., Vazquez J., Stewart J. M., Mecca A. P., Katovich M. J., Ferrario C. M., Raizada M. K., Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Experimental Physiology 2005 90 5 783 790 2-s2.0-26044453206 10.1113/expphysiol.2005.031096 (Pubitemid 41406067)
60. Díez-Freire C., Vázquez J., Correa de Adjounian M. F., Ferrari M. F.R., Yuan L., Silver X., Torres R., Raizada M. K., mraizada@phys.med.ufl.edu ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiological Genomics 2006 27 1 12 19 10.1152/physiolgenomics.00312.2005 (Pubitemid 44511821)
61. Der Sarkissian S., Grobe J. L., Yuan L., Narielwala D. R., Walter G. A., Katovich M. J., Raizada M. K., Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension 2008 51 3 712 718 2-s2.0-39749202869 10.1161/HYPERTENSIONAHA.107.100693 (Pubitemid 351301525)
62. Zhao Y. X., Yin H. Q., Yu Q. T., Qiao Y., Dai H. Y., Zhang M. X., Zhang L., Liu Y. F., Wang L. C., Liu D. S., Deng B. P., Zhang Y. H., Pan C. M., Song H. D., Qu X., Jiang H., Liu C. X., Lu X. T., Liu B., Gao F., Dong B., ACE2 overexpression ameliorates left ventricular remodeling and dysfunction in a rat model of myocardial infarction. Human Gene Therapy 2010 21 11 1545 1554 2-s2.0-78649337583 10.1089/hum.2009.160
63. Santos R. A. S., Brosnihan K. B., Chappell M. C., Pesquero J., Chernicky C. L., Greene L. J., Ferrario C. M., Converting enzyme activity and angiotensin metabolism in the dog brainstem. Hypertension 1988 11 2 I153 I157 2-s2.0-0023924404
64. Schiavone M. T., Santos R. A. S., Brosnihan K. B., Khosla M. C., Ferrario C. M., Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(17) heptapeptide. Proceedings of the National Academy of Sciences of the United States of America 1988 85 11 4095 4098 2-s2.0-0000254274
65. Averill D. B., Ishiyama Y., Chappell M. C., Ferrario C. M., Cardiac angiotensin-(17) in ischemic cardiomyopathy. Circulation 2003 108 17 2141 2146 2-s2.0-0141976060 10.1161/01.CIR.0000092888.63239.54 (Pubitemid 37337592)
66. Santos R. A. S., Castro C. H., Gava E., Pinheiro S. V. B., Almeida A. P., De Paula R. D., Cruz J. S., Ramos A. S., Rosa K. T., Irigoyen M. C., Bader M., Alenina N., Kitten G. T., Ferreira A. J., Impairment of in vitro and in vivo heart function in angiotensin-(17) receptor Mas knockout mice. Hypertension 2006 47 5 996 1002 2-s2.0-33646161714 10.1161/01.HYP.0000215289.51180.5c (Pubitemid 44297574)
67. Santos R. A. S., Brosnihan K. B., Jacobsen D. W., DiCorleto P. E., Ferrario C. M., Production of angiotensin-(17) by human vascular endothelium. Hypertension 1992 19 2 II56 II61 2-s2.0-0026513413
68. Ferreira A. J., Santos R. A., Almeida A. P., Angiotensin-(17): cardioprotective effect in myocardial ischemia/reperfusion. Hypertension 2001 38 3 665 668 2-s2.0-0035461695
69. Ferreira A. J., anderson@icb.ufmg.br Moraes P. L., Foureaux G., Andrade A. B., Santos R. A.S., Almeida A. P., The angiotensin-(17)/Mas receptor axis is expressed in sinoatrial node cells of rats. Journal of Histochemistry and Cytochemistry 2011 59 8 761 768 10.1369/0022155411411712
70. Liu E., Xu Z., Li J., Yang S., Yang W., Li G., tjcardiol@126.com Enalapril, irbesartan, and angiotensin-(17) prevent atrial tachycardia-induced ionic remodeling. International Journal of Cardiology 2011 146 3 364 370 10.1016/j.ijcard.2009.07.015
71. Loot A. E., Roks A. J. M., Henning R. H., Tio R. A., Suurmeijer A. J. H., Boomsma F., Van Gilst W. H., Angiotensin-(17) attenuates the development of heart failure after myocardial infarction in rats. Circulation 2002 105 13 1548 1550 2-s2.0-0037007055 10.1161/01.CIR.0000013847.07035.B9 (Pubitemid 34297630)
72. Ferreira A. J., Santos R. A. S., Almeida A. P., Angiotensin-(17) improves the post-ischemic function in isolated perfused rat hearts. Brazilian Journal of Medical and Biological Research 2002 35 9 1083 1090 2-s2.0-0036762878 (Pubitemid 35476807)
73. Castro C. H., Santos R. A. S., Ferreira A. J., Bader M., Alenina N., Almeida A. P., Effects of genetic deletion of angiotensin-(17) receptor Mas on cardiac function during ischemia/reperfusion in the isolated perfused mouse heart. Life Sciences 2006 80 3 264 268 2-s2.0-33845211685 10.1016/j.lfs.2006.09. 007 (Pubitemid 44853993)
74. Pan C. H., Wen C. H., Lin C. S., Interplay of angiotensin II and angiotensin(17) in the regulation of matrix metalloproteinases of human cardiocytes. Experimental Physiology 2008 93 5 599 612 2-s2.0-42649117475 10.1113/expphysiol.2007.041830 (Pubitemid 351595058)
75. Pei Z., Meng R., Li G., Yan G., Xu C., Zhuang Z., Ren J., Wu Z., Angiotensin-(17) ameliorates myocardial remodeling and interstitial fibrosis in spontaneous hypertension: role of MMPs/TIMPs. Toxicology Letters 2010 199 2 173 181 2-s2.0-77957966931 10.1016/j.toxlet.2010.08.021
76. Dias-Peixoto M. F., Santos R. A. S., Gomes E. R. M., Alves M. N. M., Almeida P. W. M., Greco L., Rosa M., Fauler B., Bader M., Alenina N., Guatimosim S., Molecular mechanisms involved in the angiotensin-(17)/Mas signaling pathway in cardiomyocytes. Hypertension 2008 52 3 542 548 2-s2.0-52049095952 10.1161/HYPERTENSIONAHA.108.114280
77. Gomes E. R. M., Lara A. A., Almeida P. W. M., Guimarães D., Resende R. R., Campagnole-Santos M. J., Bader M., Santos R. A. S., Guatimosim S., Angiotensin-(17) prevents cardiomyocyte pathological remodeling through a nitric oxide/guanosine 3′5′-cyclic monophosphate-dependent pathway. Hypertension 2010 55 1 153 160 2-s2.0-73849095442 10.1161/HYPERTENSIONAHA.109. 143255
78. Tallant E. A., Ferrario C. M., Gallagher P. E., Angiotensin-(17) inhibits growth of cardiac myocytes through activation of the Mas receptor. American Journal of PhysiologyHeart and Circulatory Physiology 2005 289 4 H1560 H1566 2-s2.0-25444473110 10.1152/ajpheart.00941.2004 (Pubitemid 41368998)
79. Giani J. F., Gironacci M. M., Muñoz M. C., Turyn D., Dominici F. P., Angiotensin-(17) has a dual role on growth-promoting signalling pathways in rat heart in vivo by stimulating STAT3 and STAT5a/b phosphorylation and inhibiting angiotensin II-stimulated ERK1/2 and Rho kinase activity. Experimental Physiology 2008 93 5 570 578 (Pubitemid 351595049)
80. Burrell L. M., Johnston C. I., Tikellis C., Cooper M. E., ACE2, a new regulator of the renin-angiotensin system. Trends in Endocrinology and Metabolism 2004 15 4 166 169 2-s2.0-1942422098 10.1016/j.tem.2004.03.001 (Pubitemid 38510496)
81. Sampaio W. O., Santos R. A. S., Faria-Silva R., Da Mata Machado L. T., Schiffrin E. L., Touyz R. M., Angiotensin-(17) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 2007 49 1 185 192 2-s2.0-33847018997 10.1161/01.HYP.0000251865. 35728.2f (Pubitemid 46360359)
82. Santos R. A. S., Ferreira A. J., Pinheiro S. V. B., Sampaio W. O., Touyz R., Campagnole-Santos M. J., Angiotensin-(17) and its receptor as a potential targets for new cardiovascular drugs. Expert Opinion on Investigational Drugs 2005 14 8 1019 1031 2-s2.0-23644452353 10.1517/13543784.14.8.1019 (Pubitemid 41131653)
83. Xu P., Costa-Goncalves A. C., Todiras M., Rabelo L. A., Sampaio W. O., Moura M. M., Santos S. S., Luft F. C., Bader M., Gross V., Alenina N., Santos R. A. S., Endothelial dysfunction and elevated blood pressure in Mas gene-deleted mice. Hypertension 2008 51 2 574 580 2-s2.0-38549174602 10.1161/HYPERTENSIONAHA. 107.102764 (Pubitemid 351156450)
84. Rabelo L. A., Alenina N., Bader M., mbader@mdc-berlin.de ACE2-angiotensin-(17)-Mas axis and oxidative stress in cardiovascular disease. Hypertension Research 2011 34 2 154 160 10.1038/hr.2010.235
85. Tallant E. A., Clark M. A., Molecular mechanisms of inhibition of vascular growth by angiotensin-(17). Hypertension 2003 42 4 574 579 2-s2.0-0141893551 10.1161/01.HYP.0000090322.55782.30 (Pubitemid 37237356)
86. Ferreira A. J., Santos R. A. S., Bradford C. N., Mecca A. P., Sumners C., Katovich M. J., Raizada M. K., Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension 2010 55 2 207 213 2-s2.0-74949087578 10.1161/HYPERTENSIONAHA.109.140145
87. Brosnihan K. B., Li P., Ferrario C. M., Angiotensin-(17) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 1996 27 3 523 528 2-s2.0-0029926375 (Pubitemid 26086221)
88. Porsti I., Bara A. T., Busse R., Hecker M., Release of nitric oxide by angiotensin-(17) from porcine coronary endothelium: implications for a novel angiotensin receptor. British Journal of Pharmacology 1994 111 3 652 654 2-s2.0-0028275331 (Pubitemid 24151646)
89. Feterik K., Smith L., Katusic Z. S., Angiotensin-(17) causes endothelium-dependent relaxation in canine middle cerebral artery. Brain Research 2000 873 1 75 82 2-s2.0-0034604779 10.1016/S0006-8993(00)02482-3 (Pubitemid 30468487)
90. Meng W., Busija D. W., Comparative effects of angiotensin-(17) and angiotensin II on piglet pial arterioles. Stroke 1993 24 12 2041 2045 2-s2.0-0027371196 (Pubitemid 23352740)
91. Osei S. Y., Ahima R. S., Minkes R. K., Weaver J. P., Khosla M. C., Kadowitz P. J., Differential responses to angiotensin-(17) in the feline mesenteric and hindquarters vascular beds. European Journal of Pharmacology 1993 234 1 35 42 2-s2.0-0027497895 10.1016/0014-2999(93)90703-K (Pubitemid 23093402)
92. Ren Y., Garvin J. L., Carretero O. A., Vasodilator action of angiotensin-(17) on isolated rabbit afferent arterioles. Hypertension 2002 39 3 799 802 2-s2.0-0036194890 10.1161/hy0302.104673 (Pubitemid 34252879)
93. Oliveira M. A., Fortes Z. B., Santos R. A. S., Kosla M. C., de Carvalho M. H. C., Synergistic effect of angiotensin-(17) on bradykinin arteriolar dilation in vivo. Peptides 1999 20 10 1195 1201 2-s2.0-0344069509 10.1016/S0196-9781(99)00123-0 (Pubitemid 29512440)
94. Fernandes L., Fortes Z. B., Nigro D., Tostes R. C. A., Santos R. A. S., Catelli de Carvalho M. H., Potentiation of bradykinin by angiotensin-(17) on arterioles of spontaneously hypertensive rats studied in vivo. Hypertension 2001 37 2 703 709 2-s2.0-0035092904 (Pubitemid 32199053)
95. Sasaki S., Higashi Y., Nakagawa K., Matsuura H., Kajiyama G., Oshima T., Effects of angiotensin-(17) on forearm circulation in normotensive subjects and patients with essential hypertension. Hypertension 2001 38 1 90 94 (Pubitemid 34224777)
96. Bayorh M. A., Eatman D., Walton M., Socci R. R., Thierry-Palmer M., Emmett N., 1A-779 attenuates angiotensin-(17) depressor response in salt-induced hypertensive rats. Peptides 2002 23 1 57 64 2-s2.0-0036007456 10.1016/S0196-9781(01)00579-4 (Pubitemid 34113763)
97. Li P., Chappell M. C., Ferrario C. M., Brosnihan K. B., Angiotensin-(17) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension 1997 29 1 394 400 2-s2.0-0031034312 (Pubitemid 27074074)
98. Walters P. E., Gaspari T. A., Widdop R. E., Angiotensin-(17) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension 2005 45 5 960 966 2-s2.0-18244391184 10.1161/01.HYP.0000160325. 59323.b8 (Pubitemid 40628944)
99. Silva D. M. R., Vianna H. R., Cortes S. F., Campagnole-Santos M. J., Santos R. A. S., Lemos V. S., Evidence for a new angiotensin-(17) receptor subtype in the aorta of Sprague-Dawley rats. Peptides 2007 28 3 702 707 2-s2.0-33846799192 10.1016/j.peptides.2006.10.007 (Pubitemid 46204993)
100. Muthalif M. M., Benter I. F., Uddin M. R., Harper J. L., Malik K. U., Signal transduction mechanisms involved in angiotensin-(17)-stimulated arachidonic acid release and prostanoid synthesis in rabbit aortic smooth muscle cells. Journal of Pharmacology and Experimental Therapeutics 1998 284 1 388 398 2-s2.0-0031912569 (Pubitemid 28109570)
101. Pinheiro S. V. B., Simões e Silva A. C., Sampaio W. O., De Paula R. D., Mendes E. P., Bontempo E. D., Pesquero J. B., Walther T., Alenina N., Bader M., Bleich M., Santos R. A. S., Nonpeptide AVE 0991 is an angiotensin-(17) receptor Mas agonist in the mouse kidney. Hypertension 2004 44 4 490 496 2-s2.0-4644372221 10.1161/01.HYP.0000141438.64887.42 (Pubitemid 39281501)
102. Faria-Silva R., Duarte F. V., Santos R. A., Short-term angiotensin(17) receptor Mas stimulation improves endothelial function in normotensive rats. Hypertension 2005 46 4 948 952 2-s2.0-33644637224
103. Roks A. J. M., Van Geel P. P., Pinto Y. M., Buikema H., Henning R. H., De Zeeuw D., Van Gilst W. H., Angiotensin-(17) is a modulator of the human renin-angiotensin system. Hypertension 1999 34 2 296 301 2-s2.0-0032820247 (Pubitemid 29409231)
104. Zhong J., Zhu Z. M., Yang Y. J., Inhibition of PKC and ERK1/2 in cultured rat vascular smooth muscle cells by angiotensin-(17). Acta Physiologica Sinica 2001 53 5 361 363 2-s2.0-1542441085 (Pubitemid 33696492)
105. Hayashi N., Yamamoto K., Ohishi M., Tatara Y., Takeya Y., Shiota A., Oguro R., Iwamoto Y., Takeda M., Rakugi H., The counterregulating role of ACE2 and ACE2-mediated angiotensin 17 signaling against angiotensin II stimulation in vascular cells. Hypertension Research 2010 33 11 1182 1185 2-s2.0-78149308747 10.1038/hr.2010.147
106. Zhang J., Noble N. A., Border W. A., Huang Y., Infusion of angiotensin-(17) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis. American Journal of PhysiologyRenal Physiology 2010 298 3 F579 F588 2-s2.0-77649125799 10.1152/ajprenal.00548.2009
107. Carvalho M. B. L., Duarte F. V., Faria-Silva R., Fauler B., Da Mata Machado L. T., De Paula R. D., Campagnole-Santos M. J., Santos R. A. S., Evidence for Mas-mediated bradykinin potentiation by the angiotensin-(17) nonpeptide mimic AVE 0991 in normotensive rats. Hypertension 2007 50 4 762 767 2-s2.0-34548840277 10.1161/HYPERTENSIONAHA.107.094987 (Pubitemid 47442743)
108. Ueda S., Masumori-Maemoto S., Wada A., Ishii M., Brosnihan K. B., Umemura S., Angiotensin(17) potentiates bradykinin-induced vasodilatation in man. Journal of Hypertension 2001 19 11 2001 2009 2-s2.0-0034755769 10.1097/00004872-200111000-00010 (Pubitemid 33035805)
109. Lima C. V., Paula R. D., Resende F. L., Khosla M. C., Santos R. A. S., Potentiation of the hypotensive effect of bradykinin by short-term infusion of angiotensin-(17) in normotensive and hypertensive rats. Hypertension 1997 30 3 542 548 2-s2.0-0030765388 (Pubitemid 27444229)
110. Almeida A. P., Frábregas B. C., Madureira M. M., Santos R. J. S., Campagnole-Santos M. J., Santos R. A. S., Angiotensin-(17) potentiates the coronary vasodilatatory effect of bradykinin in the isolated rat heart. Brazilian Journal of Medical and Biological Research 2000 33 6 709 713 2-s2.0-0342646962 (Pubitemid 30428611)
111. Lovren F., Pan Y., Quan A., Teoh H., Wang G., Shukla P. C., Levitt K. S., Oudit G. Y., Al-Omran M., Stewart D. J., Slutsky A. S., Peterson M. D., Backx P. H., Penninger J. M., Verma S., Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. American Journal of PhysiologyHeart and Circulatory Physiology 2008 295 4 H1377 H1384 2-s2.0-57049183645 10.1152/ajpheart.00331.2008
112. Rentzsch B., Todiras M., Iliescu R., Popova E., Campos L. A., Oliveira M. L., Baltatu O. C., Santos R. A., Bader M., Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function. Hypertension 2008 52 5 967 973 2-s2.0-55949126600 10.1161/HYPERTENSIONAHA.108.114322
113. Hernández Prada J. A., Ferreira A. J., Katovich M. J., Shenoy V., Qi Y., Santos R. A. S., Castellano R. K., Lampkins A. J., Gubala V., Ostrov D. A., Raizada M. K., Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 2008 51 5 1312 1317 2-s2.0-42349105833 10.1161/HYPERTENSIONAHA.107. 108944 (Pubitemid 351555943)
114. Ikram H., Maslowski A. H., Nicholls M. G., Haemodynamic and hormonal effects of captopril in primary pulmonary hypertension. British Heart Journal 1982 48 6 541 545 2-s2.0-0020459780 (Pubitemid 13217289)
115. Ghazi-Khansari M., Mohammadi-Karakani A., Sotoudeh M., Mokhtary P., Pour-Esmaeil E., Maghsoud S., Antifibrotic effect of captopril and enalapril on paraquat-induced lung fibrosis in rats. Journal of Applied Toxicology 2007 27 4 342 349 2-s2.0-34447503424 10.1002/jat.1212 (Pubitemid 47066762)
116. Li X., Molina-Molina M., Abdul-Hafez A., Uhal V., Xaubet A., Uhal B. D., Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis. American Journal of PhysiologyLung Cellular and Molecular Physiology 2008 295 1 L178 L185 2-s2.0-49049116190 10.1152/ajplung.00009.2008
117. Ferreira A. J., Shenoy V., Yamazato Y., Sriramula S., Francis J., Yuan L., Castellano R. K., Ostrov D. A., Oh S. P., Katovich M. J., Raizada M. K., Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine 2009 179 11 1048 1054 2-s2.0-66249133083 10.1164/rccm.200811-1678OC
118. Yamazato Y., Ferreira A. J., Hong K.-H., Sriramula S., Francis J., Yamazato M., Yuan L., Bradford C. N., Shenoy V., Oh S. P., Katovich M. J., Raizada M. K., mraizada@phys.med.ufl.edu Prevention of pulmonary hypertension by angiotensin-converting enzyme 2 gene transfer. Hypertension 2009 54 2 365 371 10.1161/HYPERTENSIONAHA.108.125468
119. Hamming I., Timens W., w.timens@path.azg.nl Bulthuis M. L.C., Lely A. T., Navis G. J., van Goor H., Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. Journal of Pathology 2004 203 2 631 637 10.1002/path.1570 (Pubitemid 38714099)
120. Baginski L., Tachon G., Falson F., Patton J. S., Bakowsky U., Ehrhardt C., ehrhardc@tcd.ie Reverse Transcription Polymerase Chain Reaction (RT-PCR) analysis of proteolytic enzymes in cultures of human respiratory epithelial cells. Journal of Aerosol Medicine and Pulmonary Drug Delivery 2011 24 2 89 101 10.1089/jamp.2010.0842
121. Treml B., Neu N., Kleinsasser A., Gritsch C., Finsterwalder T., Geiger R., Schuster M., Janzek E., Loibner H., Penninger J., Loeckinger A., Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets. Critical Care Medicine 2010 38 2 596 601 2-s2.0-74949134345 10.1097/CCM.0b013e3181c03009
122. Uhal B. D., uhal@msu.edu Li X., Xue A., Gao X., Abdul-Hafez A., Regulation of alveolar epithelial cell survival by the ACE-2/angiotensin 17/ Mas axis. American Journal of PhysiologyLung Cellular and Molecular Physiology 2011 301 3 L269 L274 10.1152/ajplung.00222.2010
123. Feng Y., Wan H., Liu J., Zhang R., Ma Q., Han B., Xiang Y., Che J., Cao H., Fei X., Qiu W., The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancer. Oncology Reports 2010 23 4 941 948 2-s2.0-77949442547 10.3892/or-00000718
124. Feng Y., Ni L., Wan H., hywanfy@yahoo.com.cn Fan L., Fei X., Ma Q., Gao B., Xiang Y., Che J., Li Q., liqingyun68@yahoo.com.cn Overexpression of ACE2 produces antitumor effects via inhibition of angiogenesis and tumor cell invasion in vivo and in vitro. Oncology Reports 2011 26 5 1157 1164 10.3892/or.2011.1394
125. Gallagher P. E., Tallant E. A., Inhibition of human lung cancer cell growth by angiotensin-(17). Carcinogenesis 2004 25 11 2045 2052 2-s2.0-8844265279 10.1093/carcin/bgh236 (Pubitemid 39534840)
126. Menon J., Soto-Pantoja D. R., Callahan M. F., Cline J. M., Ferrario C. M., Tallant E. A., Gallagher P. E., Angiotensin-(17) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Research 2007 67 6 2809 2815 2-s2.0-34047256118 10.1158/0008-5472.CAN-06-3614 (Pubitemid 46548970)
127. Soto-Pantoja D. R., Menon J., Gallagher P. E., Tallant E. A., Angiotensin-(17) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Molecular Cancer Therapeutics 2009 8 6 1676 1683 2-s2.0-67649366366 10.1158/1535-7163.MCT-09-0161
128. Unger T., The role of the renin-angiotensin system in the development of cardiovascular disease. The American Journal of Cardiology 2002 89 2 3A 9A 2-s2.0-0037165229
129. Kucharewicz I., Pawlak R., Matys T., Pawlak D., Buczko W., Antithrombotic effect of captopril and losartan is mediated by angiotensin-(17). Hypertension 2002 40 5 774 779 2-s2.0-0036841147 10.1161/01.HYP.0000035396.27909.40 (Pubitemid 35278618)
130. Iyer S. N., Chappell M. C., Averill D. B., Diz D. I., Ferrario C. M., Vasodepressor actions of angiotensin-(17) unmasked during combined treatment with lisinopril and losartan. Hypertension 1998 31 2 699 705 2-s2.0-0031935350
131. Collister J. P., Hendel M. D., The role of Ang (17) in mediating the chronic hypotensive effects of losartan in normal rats. Journal of the Renin-Angiotensin-Aldosterone System 2003 4 3 176 179 2-s2.0-0242661899 (Pubitemid 37419854)
132. Yamada K., Iyer S. N., Chappell M. C., Ganten D., Ferrario C. M., Converting enzyme determines plasma clearance of angiotensin-(17). Hypertension 1998 32 3 496 502 2-s2.0-0031683009 (Pubitemid 28429139)
133. Lula I., Denadai Â. L., Resende J. M., de Sousa F. B., de Lima G. F., Pilo-Veloso D., Heine T., Duarte H. A., Santos R. A. S., Sinisterra R. D., Study of angiotensin-(17) vasoactive peptide and its β -cyclodextrin inclusion complexes: complete sequence-specific NMR assignments and structural studies. Peptides 2007 28 11 2199 2210 2-s2.0-35349001774 10.1016/j.peptides. 2007.08.011 (Pubitemid 47610792)
134. Uekama K., uekama@gpo.kumamoto-u.ac.jp Design and evaluation of cyclodextrin-based drug formulation. Chemical and Pharmaceutical Bulletin 2004 52 8 900 915 10.1248/cpb.52.900 (Pubitemid 41701863)
135. Fraga-Silva R. A., Costa-Fraga F. P., Alenina N., de Sousa F. B., Bader M., Sinisterra R. D., Santos R. A.S., santos@icb.ufmg.br An orally active formulation of angiotensin-(17) produces an antithrombotic effect. Clinics 2011 66 5 837 841 10.1590/S1807-59322011000500021
136. Marques F. D., Ferreira A. J., Sinisterra R., Jacoby B. A., Sousa F. B., Caliari M. V., Silva G. A.B., Melo M. B., Nadu A. P., Souza L. E., Irigoyen M. C.C., Almeida A. P., Santos R. A.S., santos@icb.ufmg.br An oral formulation of angiotensin-(17) produces cardioprotective effects in infarcted and isoproterenol-treated rats. Hypertension 2011 57 3 477 483 10.1161/ HYPERTENSIONAHA.110.167346
137. Silva-Barcellos N. M., Caligiorne S., Santos R. A. S., Frézard F., Site-specific microinjection of liposomes into the brain for local infusion of a short-lived peptide. Journal of Controlled Release 2004 95 2 301 307 2-s2.0-1242271287 10.1016/j.jconrel.2003.12.010 (Pubitemid 38230044)
138. Silva-Barcellos N. M., Frézard F., Caligiorne S., Santos R. A. S., Long-lasting cardiovascular effects of liposome-entrapped angiotensin-(17) at the rostral ventrolateral medulla. Hypertension 2001 38 6 1266 1271 2-s2.0-0035672041 (Pubitemid 34033400)
139. Kluskens L. D., Nelemans S. A., Rink R., De Vries L., Meter-Arkema A., Wang Y., Walther T., Kuipers A., Moll G. N., Haas M., Angiotensin-(17) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(17) analog. Journal of Pharmacology and Experimental Therapeutics 2009 328 3 849 855 2-s2.0-62449281004 10.1124/jpet.108.146431
140. Lemos V. S., Silva D. M.R., Walther T., Alenina N., Bader M., Santos R. A.S., santos@icb.ufmg.br The endothelium-dependent vasodilator effect of the nonpeptide Ang(17) mimic AVE 0991 is abolished in the aorta of Mas-knockout mice. Journal of Cardiovascular Pharmacology 2005 46 3 274 279 10.1097/01.fjc.0000175237.41573.63 (Pubitemid 41262828)
141. Wiemer G., Dobrucki L. W., Louka F. R., Malinski T., Heitsch H., AVE 0991, a nonpeptide mimic of the effects of angiotensin-(17) on the endothelium. Hypertension 2002 40 6 847 852 2-s2.0-0036900194 10.1161/01.HYP.0000037979. 53963.8F (Pubitemid 35434905)
142. Ferreira A. J., Jacoby B. A., Araújo C. A. A., Macedo F. A. F. F., Silva G. A. B., Almeida A. P., Caliari M. V., Santos R. A. S., The nonpeptide angiotensin-(17) receptor Mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction. American Journal of PhysiologyHeart and Circulatory Physiology 2007 292 2 H1113 H1119 2-s2.0-33846956137 10.1152/ajpheart.00828.2006
143. Ferreira A. J., Oliveira T. L., Castro M. C. M., Almeida A. P., Castro C. H., Caliari M. V., Gava E., Kitten G. T., Santos R. A. S., Isoproterenol- induced impairment of heart function and remodeling are attenuated by the nonpeptide angiotensin-(17) analogue AVE 0991. Life Sciences 2007 81 11 916 923 2-s2.0-34548507186 10.1016/j.lfs.2007.07.022 (Pubitemid 47374211)
144. Shemesh R., Toporik A., Levine Z., Hecht I., Rotman G., Wool A., Dahary D., Gofer E., Kliger Y., Soffer M. A., Rosenberg A., Eshel D., Cohen Y., Discovery and validation of novel peptide agonists for G-protein-coupled receptors. Journal of Biological Chemistry 2008 283 50 34643 34649 2-s2.0-58049193594 10.1074/jbc.M805181200
145. Fraga-Silva R. A., Sorg B. S., Wankhede M., deDeugd C., Jun J. Y., Baker M. B., Li Y., Castellano R. K., Katovich M. J., Raizada M. K., Ferreira A. J., ACE2 activation promotes antithrombotic activity. Molecular Medicine 2010 16 5-6 210 215 2-s2.0-77951955278 10.2119/molmed.2009.00160